PHR.WA PL Equity☆

Pricefull chart →

Mkt cap $9.1M · 1Y −12.7% · Off 52W high −28.5% · Vol (1Y) 55.6%

Key fundamentalsfull statements →

Pharmena S.A. is engaged in the sale of dietary supplements in Poland and internationally and is developing 1-MNA (the PHR-701 program), a medical device for use in difficult-to-heal wounds. The company also conducts research and development into therapeutic applications of 1-MNA as an anti-inflammatory and anti-fibrotic drug, including work on pulmonary fibrosis, respiratory tract and viral infections such as COVID-19, and inflammatory and metabolic diseases. Pharmena was founded in 2002, is based in Lodz, Poland, and operates as a subsidiary of Pelion S.A.

Snapshot

Headline riskfull risk →

Peers

No same-industry peers in the universe for PHR.WA.